Pharmaceuticals · Process Validation
Pharmaceutical Process Validation Consulting
The short answer
Process validation for a drug product is a three-stage lifecycle: design the process and its control strategy, qualify commercial-scale performance, and then verify that the process stays in control for as long as it is used. We support pharmaceutical manufacturers across all three stages, and we most often get called because Stage 1 knowledge was never documented well enough to defend the Stage 2 acceptance criteria.
01
Why this matters
- Process performance qualification runs are expensive, and a PPQ executed against criteria that cannot be justified is usually repeated.
- FDA evaluates the rationale, not the binder. Acceptance criteria derived from three historical batches rather than process understanding are difficult to defend.
- Stage 3 is where most programs quietly lapse. Without continued process verification, trending and periodic review, the validated state becomes an assertion rather than a fact.
02
Applicable regulations and standards
- 21 CFR 211.100 / 211.110
- Written procedures for production and process control, and in-process control of critical steps.
- FDA Process Validation Guidance (2011)
- The three-stage lifecycle model FDA applies during evaluation of validation programs.
- ICH Q8 / Q9 / Q10
- Product and process understanding, quality risk management and the pharmaceutical quality system.
- ICH Q11
- Development and manufacture of drug substances, including control strategy expectations.
03
What our consultants actually do
- Build or repair the validation master plan and align it with the site quality system rather than leaving it as a standalone document
- Convert development and characterization data into a documented control strategy with justified critical process parameters and critical quality attributes
- Write and review PPQ protocols, sampling plans and statistically supportable acceptance criteria
- Provide on-site execution oversight, deviation triage during PPQ and technical review of the validation report
- Design Stage 3 continued process verification: trending, capability metrics, review frequency and the escalation path when trends move
- Remediate legacy validation packages for products acquired, transferred or running under superseded protocols
04
Across the product lifecycle
01 / DEVELOP
Characterization studies structured so the data can later support parameter ranges.
02 / SCALE
Scale-dependent parameters identified before commercial equipment is committed.
03 / TRANSFER
Process knowledge documented for the receiving site, not just the batch record.
04 / VALIDATE
PPQ protocol, execution oversight and a report that states what was demonstrated.
05 / MANUFACTURE
In-process controls and batch review aligned with the validated ranges.
06 / MAINTAIN
CPV trending, requalification triggers and change-driven revalidation.
05
Problems we are usually called about
- Acceptance criteria copied from the development report with no statistical basis
- PPQ deviations closed as documentation errors so the runs can be counted as successful
- Critical process parameters listed in the protocol but absent from the batch record
- No defined trigger connecting change control to revalidation
- Continued process verification reduced to an annual product review with no capability analysis
06
Typical deliverables
- Validation master plan and validation strategy document
- Control strategy summary linking CQAs, CPPs and in-process controls
- PPQ protocols, sampling plans and executed reports
- Continued process verification plan with trending methodology
- Gap assessment and prioritized remediation plan for legacy validation
07
Frequently asked
- How many PPQ batches does FDA require?
- There is no fixed number. The 2011 guidance replaced the three-batch convention with a risk- and knowledge-based justification. The number of runs must be defended by process understanding, variability and the sampling plan, and that justification belongs in the protocol.
- Can we validate a legacy product that was never formally validated?
- Yes. Legacy products are typically addressed through a documented assessment of historical data, a gap analysis against current expectations and either prospective qualification runs or a well-supported continued process verification approach. What matters is a defensible written rationale for the path chosen.
- Does a change to a raw material supplier require revalidation?
- It requires an assessment. The change control record should evaluate impact on critical quality attributes and process performance, and define whether comparability data, additional in-process monitoring or requalification runs are needed.
08
References
More for pharmaceuticals
cGMP, validation and manufacturing quality support for drug products.
- Cleaning ValidationCleaning validation demonstrates that a documented cleaning procedure consistently reduces residues to scientifically justified limits on shared equipment.
- cGMP ConsultingcGMP consulting for a drug manufacturer means making 21 CFR Parts 210 and 211 operable in your facility — with procedures your staff can follow, records that reconstruct what happened and a quality unit with the authority to act.
- Technology TransferTechnology transfer succeeds or fails on what the receiving site is given: process understanding, not just a batch record.
- Quality SystemsA pharmaceutical quality system is the set of connected processes — documents, changes, deviations, CAPA, training, release, review — that keep product decisions defensible.
- IND CMC SupportSponsors filing an IND usually need two things at once: CMC content for the application and a quality system capable of overseeing clinical manufacturing.
- NDA Manufacturing SupportThis is the site-side companion to an NDA filing: making sure the validated process, the control strategy and the records at the manufacturing site match what the application says, and that the people there can explain it during a pre-approval inspection..
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.